Stefan Pöhlmann Selected Research

SARS-CoV-2 spike protein

1/2022	Evidence for an ACE2-Independent Entry Pathway That Can Protect from Neutralization by an Antibody Used for COVID-19 Therapy.
1/2021	Inhibition of acid sphingomyelinase by ambroxol prevents SARS-CoV-2 entry into epithelial cells.
1/2021	Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods.
1/2021	Ex vivo assay to evaluate the efficacy of drugs targeting sphingolipids in preventing SARS-CoV-2 infection of nasal epithelial cells.
11/2020	Pharmacological Inhibition of Acid Sphingomyelinase Prevents Uptake of SARS-CoV-2 by Epithelial Cells.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Pöhlmann Research Topics

Disease

65	Infections 01/2022 - 04/2002
36	COVID-19 10/2022 - 01/2020
17	Virus Diseases (Viral Diseases) 01/2022 - 11/2004
9	Vesicular Stomatitis 01/2021 - 06/2004
7	Human Influenza (Influenza) 01/2022 - 07/2009
5	Ebola Hemorrhagic Fever 04/2021 - 08/2002
4	Severe Acute Respiratory Syndrome 10/2014 - 06/2004
3	Lung Injury 01/2022 - 01/2010
3	Inflammation (Inflammations) 01/2022 - 01/2021
3	Filoviridae Infections 01/2019 - 11/2004
3	Coronavirus Infections 04/2015 - 09/2014
3	Acquired Immunodeficiency Syndrome (AIDS) 01/2013 - 01/2006
2	Hemorrhage 01/2022 - 11/2021
2	Critical Illness (Critically Ill) 12/2021 - 01/2021
2	Neoplasms (Cancer) 01/2019 - 07/2009
2	Fever (Fevers) 04/2013 - 11/2011
1	Fibrosarcoma 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Weight Loss (Weight Reduction) 01/2022
1	Hypoxia (Hypoxemia) 12/2021
1	Lymphopenia (Lymphocytopenia) 12/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 12/2021
1	Coinfection 01/2021
1	Common Cold 01/2021

Drug/Important Bio-Agent (IBA)

24	Antiviral Agents (Antivirals)IBA 01/2022 - 11/2011
21	Proteins (Proteins, Gene)FDA Link 01/2022 - 06/2004
17	Peptide Hydrolases (Proteases)FDA Link 03/2021 - 01/2006
15	DC-specific ICAM-3 grabbing nonintegrin (DC-SIGN)IBA 10/2020 - 08/2002
14	AntibodiesIBA 10/2022 - 06/2004
12	VaccinesIBA 01/2022 - 05/2005
12	Glycoproteins (Glycoprotein)IBA 10/2020 - 09/2002
8	Neutralizing AntibodiesIBA 01/2022 - 06/2004
7	Serine Proteases (Serine Protease)IBA 01/2022 - 07/2009
7	LectinsIBA 10/2020 - 08/2002
6	Pharmaceutical PreparationsIBA 01/2022 - 01/2020
6	camostatIBA 01/2022 - 04/2015
6	Bone Marrow Stromal Antigen 2IBA 01/2019 - 11/2011
5	SARS-CoV-2 spike proteinIBA 01/2022 - 11/2020
5	InterferonsIBA 10/2021 - 01/2017
4	bamlanivimabIBA 01/2022 - 01/2021
4	Sphingomyelin Phosphodiesterase (Sphingomyelinase)IBA 01/2021 - 11/2020
4	Polysaccharides (Glycans)IBA 10/2020 - 01/2008
4	C-Type Lectins (C-Type Lectin)IBA 07/2011 - 01/2003
3	Monoclonal AntibodiesIBA 01/2022 - 10/2021
3	BNT162 VaccineIBA 12/2021 - 01/2021
3	AcidsIBA 01/2021 - 11/2020
3	CeramidesIBA 01/2021 - 11/2020
3	EnzymesIBA 11/2020 - 12/2011
3	Sialic AcidsIBA 01/2018 - 10/2010
2	CytokinesIBA 01/2022 - 10/2011
2	AntioxidantsIBA 01/2022 - 11/2021
2	Biological ProductsIBA 01/2022 - 11/2011
2	Sulfhydryl Compounds (Thiols)IBA 01/2022 - 11/2021
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2021
2	Cysteamine (Mercaptamine)FDA Link 01/2022 - 11/2021
2	sphingosine kinaseIBA 12/2021 - 04/2021
2	Ac-GQFR-kbtIBA 10/2021 - 05/2021
2	3,5-diisopropylsalicylic acid (DIPS)IBA 10/2021 - 01/2021
2	nafamostatIBA 10/2021 - 01/2020
2	Protease Inhibitors (Protease Inhibitor)IBA 03/2021 - 08/2020
2	Antidepressive Agents (Antidepressants)IBA 01/2021 - 11/2020
2	LigandsIBA 01/2021 - 01/2017
2	Amitriptyline (Elavil)FDA LinkGeneric 01/2021 - 11/2020
2	AntigensIBA 11/2020 - 03/2020
2	CarbohydratesIBA 10/2020 - 01/2017
2	Angiotensin-Converting Enzyme 2IBA 01/2010 - 07/2004
1	sotrovimabIBA 10/2022
1	cilgavimabIBA 10/2022
1	N-methyl-valyl-amiclenomycin (BA 2)IBA 10/2022
1	N-(2-cyanoethylene)urea (BA 1)IBA 10/2022
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2022
1	Phosphotransferases (Kinase)IBA 01/2022
1	Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)IBA 01/2022
1	Mitogen-Activated Protein KinasesIBA 01/2022
1	2- (2- chloro- 4- iodophenylamino)- N- 3,4- difluorobenzoic acidIBA 01/2022
1	PeptidomimeticsIBA 01/2022
1	AerosolsIBA 01/2022
1	imdevimabIBA 01/2022
1	LyasesIBA 12/2021
1	sphingosine 1-phosphate (sphingosine-1-phosphate)IBA 12/2021
1	LipidsIBA 12/2021
1	HDL LipoproteinsIBA 12/2021
1	Serum AlbuminIBA 12/2021
1	2019-nCoV Vaccine mRNA-1273IBA 12/2021
1	otamixabanIBA 10/2021
1	casirivimabIBA 01/2021
1	SphingolipidsIBA 01/2021
1	Biomarkers (Surrogate Marker)IBA 01/2021
1	Peptide LibraryIBA 01/2021
1	Anti-Inflammatory Agents (Anti-Inflammatories)IBA 01/2021
1	ChemokinesIBA 01/2021
1	Nucleocapsid ProteinsIBA 01/2021
1	Expectorants (Mucolytics)IBA 01/2021
1	CyclohexanolsIBA 01/2021
1	dalbavancinIBA 01/2021
1	Cystatin CIBA 01/2021
1	Membrane Proteins (Integral Membrane Proteins)IBA 01/2021
1	Ambroxol (Mucosolvan)IBA 01/2021

Therapy/Procedure

13	Therapeutics 10/2022 - 08/2002
1	Critical Care (Surgical Intensive Care) 01/2021